Glaxo Wellcome: top of the class for small molecules; where in genomics?

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.8, Iss.2, 1998-02, pp. : 103-109

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The antiviral valaciclovir [`Valtrex'; Glaxo Wellcome] has been launched in Japan

Inpharma, Vol. 1, Iss. 1260, 2000-01 ,pp. : 22-22

Adis International

Access to resources Recommend Favorite

APPLICATIONS OF PHARMACOGENETICS TO DRUG DEVELOPMENT: THE GLAXO WELLCOME EXPERIENCE1 *

By ARLEDGE TERESA FREEMAN ANDREW ARBUCKLE JULIAN MOSTELLER MICHAEL MANASCO PENELOPE

Drug Metabolism Reviews, Vol. 32, Iss. 3-4, 2000-10 ,pp. : 387-394

Informa Healthcare

Access to resources Recommend Favorite

Chemical Genomics: Probing Protein Function Using Small Molecules

By Bridget K. Wagner Stephen J. Haggarty Paul A. Clemons

American Journal of PharmacoGenomics, Vol. 4, Iss. 5, 2004-01 ,pp. : 313-320

Adis International

Access to resources Recommend Favorite

Lamivudine [`Zeffix'; Glaxo Wellcome] has been launched in a new indication in New Zealand

Inpharma, Vol. 1, Iss. 1259, 2000-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite

Inflammatory Mechanisms in Atherosclerosis, Glaxo-Wellcome Medicines Research Centre, Stevenage, Herts, UK, 3rd July 1995

By Black D. Reilly C. F.

Inflammation Research, Vol. 46, Iss. 7, 1997-07 ,pp. : 237-241

Springer Publishing Company

Access to resources Recommend Favorite